ADC Therapeutics SA (ADCT) Tops Q1 EPS by 18c

ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.22), $0.18 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.03 million versus the consensus estimate of $17.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• BofA Securities Reinstates Zoom Video (ZM) at Buy
• Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
• Barclays on Workday (WDAY): 'we see volatility risk if WDAY comments on Reuters' acquisition news'